(Q36060018)

11 August 2017

Estimation of utilities for chronic hepatitis C from SF-36 scores (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

Hla-Hla Thein

1

0 references

Murray Krahn

object named as

Murray Krahn

series ordinal

2

0 references

John Kaldor

series ordinal

3

object named as

John M Kaldor

1 reference

11 August 2017

4

Gregory J Dore

1 reference

PubMed ID

15743364

11 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

The American Journal of Gastroenterology

11 August 2017

1 reference

11 August 2017

100

1 reference

11 August 2017

643-651

1 reference

11 August 2017

3

1 reference

Is severe liver disease a common outcome for people with chronic hepatitis C?

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Utility approach to measuring health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Quality of life assessment for cost/utility studies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Deriving a preference-based single index from the UK SF-36 Health Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

The estimation of a preference-based measure of health from the SF-36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Subclinical impairment of brain function in chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

The impact of diagnosis of hepatitis C virus on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

When does quality-adjusting life-years matter in cost-effectiveness analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Reversibility of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Patient and Community Preferences for Outcomes in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Health-State Utilities and Quality of Life in Hepatitis C Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

Can the Health Utilities Index Measure Change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40976.X

10.1111/J.1572-0241.2005.40976.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15743364